Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24966594 | 0.89 | ALDH1A1 (0.42) | ALDH1A1CYP3A4LMNAHSD17B10CA2 | |
| SCHEMBL15488970 | 0.81 | ALDH1A1 (0.37) | ALDH1A1CYP3A4LMNAHSD17B10CA2 | |
| SCHEMBL7604354 | 0.81 | ALDH1A1 (0.38) | ALDH1A1CYP3A4LMNAHSD17B10CA2 | |
| SCHEMBL8472511 | 0.80 | ALDH1A1 (0.36) | ALDH1A1CYP3A4LMNAHSD17B10CA2 | |
| SCHEMBL23685460 | 0.79 | ALDH1A1 (0.35) | ALDH1A1CYP3A4LMNAHSD17B10CA2 | |
| SCHEMBL23685501 | 0.77 | ALDH1A1 (0.34) | ALDH1A1CYP3A4LMNAHSD17B10CA2 | |
| SCHEMBL13415633 | 0.76 | ALDH1A1 (0.36) | ALDH1A1CYP3A4LMNAHSD17B10CA2 | |
| SCHEMBL7606355 | 0.75 | ALDH1A1 (0.35) | ALDH1A1CYP3A4LMNAHSD17B10CA2 | |
| SCHEMBL9945573 | 0.72 | ALDH1A1 (0.57) | ALDH1A1CYP3A4LMNAPTGS1TSHR | |
| SCHEMBL14010067 | 0.71 | ALDH1A1 (0.40) | ALDH1A1CYP3A4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| EP-2447264-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010150840-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | REN, AGTR1, AGTR2 | ALDH1A1 484/4885CYP3A4 408/4885LMNA 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.